Together, these data suggest NADPH oxidases, particularly NOX4, may play a role in the progression of fibrotic pathologies, such as IPF and PBC, implicating selective NADPH oxidase inhibitors as promising therapeutic agents. Here, FMO5 is linked to idiopathic pulmonary fibrosis.